- Zacks Small Cap Research•2 days ago
On Nov. 29, Oramed (ORMP) announced that it successfully concluded a Phase Ib study of ORMD-0901, the Company’s proprietary oral GLP-1 analog. This ex-US Phase Ib study of ORMD-0901 is conducted in Israel. Currently Oramed is preparing to submit an IND with the FDA and anticipate initiating a Phase IIb study in 2017.
- PR Newswire•3 days ago
JERUSALEM, Nov. 29, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced it successfully concluded a Phase Ib study of ORMD-0901, the Company's proprietary oral GLP-1 analog. The Phase Ib study on type 2 diabetic patients showed ORMD-0901 to be safe and well tolerated, having no serious adverse events, adverse events or abnormal laboratory findings during the study. In addition, the active oral GLP-1 arms of the study showed encouraging trending efficacy. Currently we are preparing to submit an IND with the FDA and anticipate initiating a Phase IIb study in 2017," said Oramed CEO Nadav Kidron.
- PR Newswire•2 months ago
Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced it has received an additional milestone payment of $4 million from Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT). This milestone is part of a previously-announced license and investment agreement between Oramed and HTIT, and follows recent milestone payments of $4 million and $6.5 million. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
ORMP : Summary for Oramed Pharmaceuticals Inc. - Yahoo Finance
Oramed Pharmaceuticals Inc. (ORMP)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||3.14 x 100|
|Ask||7.45 x 1000|
|Day's Range||5.98 - 6.34|
|52 Week Range||5.60 - 10.51|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-7.19|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|